Efficient responses in a murine renal tumor model by electroloading dendritic cells with whole-tumor lysate

Journal of Immunotherapy

Volumn 28, Issue 6, 2005, Pages 542-550

  Weiss, Jonathan M ^a   Allen, Cornell ^a   Shivakumar, Rama ^a   Feller, Stephanie ^a   Li, Lin Hong ^a   Liu, Linda N ^a,b  

^a MAXCYTE INC   (United States)

^b NONE   (United States)

Author keywords

Dendritic cells; Electroporation; Immunotherapy; Mouse tumor models; Whole tumor lysate

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELL LYSATE; CONTROLLED STUDY; CRYOPRESERVATION; CYTOLYSIS; DENDRITIC CELL; ELECTROPORATION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; KIDNEY CARCINOMA; LEWIS CARCINOMA; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR MODEL; TUMOR VOLUME;

EID: 27444433235     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000179437.95335.23     Document Type: Article

References (39)

1. Heufler C, Koch F, Stanzl U, et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol. 1996;26:659-668.
2. Granucci F, Zanoni I, Feau S, et al. Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. EMBO J. 2003;22:2546-2551.
3. Sallusto F, Cella M, Danieli C, et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. 1995;182:389-400.
4. Lohmann S, Galle K, Knop J, et al. CD83+ human dendritic cells transfected with tumor peptide cDNA by electroporation induce specific T-cell responses: a potential tool for gene immunotherapy. Cancer Gene Ther. 2000;7:605-614.
5. Panelli MC, Wunderlich J, Jeffries J, et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother. 2000;23:487-498.
6. Ueda Y, Itoh T, Nukaya I, et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol. 2004;24:909-917.
7. Schultz ES, Schuler-Thumer B, Stroobant V, et al. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J Immunol. 2004;172:1304-1310.
8. Berard F, Blanco P, Davoust J, et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med. 2000;192:1535-1544.
9. Bonehill A, Heirman C, Tuyaerts S, et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol. 2004;172:6649-6657.
10. Kalady MF, Onaitis MW, Emani S, et al. Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. J Gastrointest Surg. 2004;8:175-182.
11. Shibagaki N, Udey MC. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol. 2002;168:2393-2401.
12. Reeves ME, Royal RE, Lam JS, et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 1996; 56:5672-5677.
13. Okada N, Iiyama S, Okada Y, et al. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Cancer Gene Ther. 2005;12:72-83.
14. Shibagaki N, Udey MC. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol. 2003;33:850-860.
15. Parkhurst MR, DePan C, Riley JP, et al. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol. 2003;170: 5317-5325.
16. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004;10:4699-4708.
17. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
18. Vidovic D, Graddis T, Chen F, et al. Antitumor vaccination with HER-2-derived recombinant antigens. Int J Cancer. 2002;102:660-664.
19. He LZ, Ramakrishna V, Connolly JE, et al. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta. Clin Cancer Res. 2004;10:1920-1927.
20. Ramakrishna V, Treml JF, Vitale L, et al. Mannose receptor targeting of tumor antigen pme117 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol. 2004;172:2845-2852.
21. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA. 1998;95:9482-9487.
22. Holtl L, Zelle-Rieser C, Gander H, et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res. 2002;8:3369-3376.
23. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001;61: 8513-8519.
24. Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 2001; 61:6445-6450.
25. Wen YJ, Min R, Tricot G, et al. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood. 2002;99:3280-3285.
26. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64:4973-4979.
27. Fratantoni JC, Dzekunov S, Singh V, et al. A non-viral gene delivery system designed for clinical use. Cytotherapy. 2003;5:208-210.
28. Weiss JM, Shivakumar R, Feller S, et al. Rapid, in vivo, evaluation of antiangiogenic and antineoplastic gene products by nonviral transfection of tumor cells. Cancer Gene Ther. 2004;11:346-353.
29. Heller LC, Ingram SF, Lucas ML, et al. Effect of electrically mediated intratumor and intramuscular delivery of a plasmid encoding IFN alpha on visible B16 mouse melanomas. Technol Cancer Res Treat. 2002;1:205-209.
30. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24:148-154.
31. Morse MA, Mosca PJ, Clay TM, et al. Dendritic cell maturation in active immunotherapy strategies. Expert Opin Biol Ther. 2002;2:35-43.
32. Chang AE, Redman BG, Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res. 2002;8:1021-1032.
33. Gatza E, Okada CY. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J Immunol. 2002;169:5227-5235.
34. Herr W, Ranieri E, Olson W, et al. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood. 2000;96:1857-1864.
35. Thumann P, Moc I, Humrich J, et al. Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods. 2003;277: 1-16.
36. Kim KW, Kim SH, Jang JH, et al. Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity. Cancer Immunol Immunother. 2004;53:315-322.
37. Shu SY, Chou T, Rosenberg SA. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol. 1987;139:295-304.
38. Chhabra A, Mehrotra S, Chakraborty NG, et al. Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation. Eur J Immunol. 2004;34:2824-2833.
39. Wang HY, Fu T, Wang G, et al. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest. 2002;109:1463-1470.